|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parker JS, Mullins M, Cheang MCU, Leung S,
Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al:
Supervised risk predictor of breast cancer based on intrinsic
subtypes. J Clin Oncol. 27:1160–1167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Botti G, Cantile M, Collina F, Cerrone M,
Sarno S, Anniciello A and Di Bonito M: Morphological and
pathological features of basal-like breast cancer. Transl Cancer
Res. 8 (Suppl 5):S503–S509. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Q, Xu M, Sun Y, Chen J, Chen C, Qian
C, Chen Y, Cao L, Xu Q, Du X and Yang W: Gene Expression profiling
for diagnosis of triple-negative breast cancer: A multicenter,
retrospective cohort study. Front Oncol. 9:3542019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riaz N, Idress R, Habib S and Lalani EN:
Lack of androgen receptor expression selects for basal-like
phenotype and is a predictor of poor clinical outcome in
non-metastatic triple negative breast cancer. Fron Oncol.
10:10832020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dent R, Hanna WM, Trudeau M, Rawlinson E,
Sun P and Narod SA: Pattern of metastatic spread in triple-negative
breast cancer. Breast Cancer Res Treat. 115:423–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cine N, Baykal AT, Sunnetci D, Canturk Z,
Serhatli M and Savli H: Identification of ApoA1, HPX and POTEE
genes by omic analysis in breast cancer. Oncol Rep. 32:1078–1086.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dufresne J, Bowden P, Thavarajah T,
Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT,
Phan M, Mohamed N, et al: The plasma peptides of breast versus
ovarian cancer. Clin Proteomics. 16:432019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mineo C and Shaul PW: Novel biological
functions of high-density lipoprotein cholesterol. Circ Res.
111:1079–1090. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu JX, Yuan Q, Min YL, He Y, Xu QH, Li B,
Shi WQ, Lin Q, Li QH, Zhu PW and Shao Y: Apolipoprotein A1 and B as
risk factors for development of intraocular metastasis in patients
with breast cancer. Cancer Manag Res. 11:2881–2888. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marinho AT, Lu H, Pereira SA, Monteiro E,
Gabra H and Recchi C: Anti-tumorigenic and platinum-sensitizing
effects of apolipoprotein A1 and apolipoprotein A1 Mimetic Peptides
In Ovarian Cancer. Front Pharmacol. 9:15242019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aguirre-Portolés C, Feliu J, Reglero G and
Ramírez de Molina A: ABCA1 overexpression worsens colorectal cancer
prognosis by facilitating tumour growth and caveolin-1-dependent
invasiveness, and these effects can be ameliorated using the BET
inhibitor apabetalone. Mol Oncol. 12:1735–1752. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sirniö P, Väyrynen JP, Klintrup K, Mäkelä
J, Mäkinen MJ, Karttunen TJ and Tuomisto A: Decreased serum
apolipoprotein A1 levels are associated with poor survival and
systemic inflammatory response in colorectal cancer. Sci Rep.
7:53742017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mao M, Wang X, Sheng H, Liu Y, Zhang L,
Dai S and Chi PD: A novel score based on serum apolipoprotein A-1
and C-reactive protein is a prognostic biomarker in hepatocellular
carcinoma patients. BMC Cancer. 18:11782018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao F, Vasquez SX, Su F, Roberts S, Shah
N, Grijalva V, Imaizumi S, Chattopadhyay A, Ganapathy E, Meriwether
D, et al: L-5F, an apolipoprotein A-I mimetic, inhibits tumor
angiogenesis by suppressing VEGF/basic FGF signaling pathways.
Integr Biol (Camb). 3:479–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zamanian-Daryoush M, Lindner D, Tallant
TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D,
Parsons-Wingerter P, Rayman P, et al: The cardioprotective protein
apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol
Chem. 288:21237–21252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun K, Lv H, Chen B, Nie C, Zhao J, Wang
S, Wang J, Xu W and Chen X: Dawning precision treatment for gastric
cancer: The latest biomarkers. J Transl Int Med. 9:228–230. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karauzum I, Karauzum K, Acar B, Hanci K,
Bildirici HIU, Kilic T and Ural E: Predictive value of
lymphocyte-to-monocyte ratio in patients with contrast-induced
nephropathy after percutaneous coronary intervention for acute
coronary syndrome. J Transl Int Med. 9:123–130. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan S, Sun S, Liu B and Hou Y: Pan-cancer
landscape of the RUNX protein family reveals their potential as
carcinogenic biomarkers and the mechanisms underlying their action.
J Transl Int Med. 10:156–174. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Y, Meng Z, Zhang L and Liu F: CD2 is
a novel immune-related prognostic biomarker of invasive breast
carcinoma that modulates the tumor microenvironment. Front Immunol.
12:6648452021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ha Y, Kim D, Han S, Chon YE, Lee YB, Kim
MN, Lee JH, Park H, Rim KS and Hwang SG: Sarcopenia predicts
prognosis in patients with newly diagnosed hepatocellular
carcinoma, independent of tumor stage and liver function. Cancer
Res Treat. 50:843–851. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeng W, Xiong G, Hua L, Hu Y, Guo X and
Peng X: APOA1 mRNA and protein in kidney renal clear cell carcinoma
correlate with the disease outcome. Sci Rep. 12:124062022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo Y, Huang B, Li R, Li J, Tian S, Peng C
and Dong W: Low APOA-1 expression in hepatocellular carcinoma
patients is associated with DNA methylation and poor overall
survival. Front Genet. 12:7607442021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li E, Bestor TH and Jaenisch R: Targeted
mutation of the DNA methyltransferase gene results in embryonic
lethality. Cell. 69:915–926. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jaenisch R and Bird A: Epigenetic
regulation of gene expression: How the genome integrates intrinsic
and environmental signals. Nat Genet. 33 (Suppl):S245–S254. 2003.
View Article : Google Scholar
|
|
29
|
Greenberg MVC and Bourc'his D: The diverse
roles of DNA methylation in mammalian development and disease. Nat
Rev Mol Cell Biol. 20:590–607. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grosser K and Metzler D: Modeling
methylation dynamics with simultaneous changes in CpG islands. BMC
Bioinformatics. 21:1152020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hellman A and Chess A: Gene body-specific
methylation on the active X chromosome. Science. 315:1141–1143.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ball MP, Li JB, Gao Y, Lee JH, LeProust
EM, Park IH, Xie B, Daley GQ and Church GM: Targeted and
genome-scale strategies reveal gene-body methylation signatures in
human cells. Nat Biotechnol. 27:361–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aran D, Toperoff G, Rosenberg M and
Hellman A: Replication timing-related and gene body-specific
methylation of active human genes. Hum Mol Genet. 20:670–680. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jjingo D, Conley AB, Yi SV, Lunyak VV and
Jordan IK: On the presence and role of human gene-body DNA
methylation. Oncotarget. 3:462–474. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Roadmap Epigenomics Consortium, . Kundaje
A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A,
Kheradpour P, Zhang Z, Wang J, et al: Integrative analysis of 111
reference human epigenomes. Nature. 518:317–330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cowan LA, Talwar S and Yang AS: Will DNA
methylation inhibitors work in solid tumors? A review of the
clinical experience with azacitidine and decitabine in solid
tumors. Epigenomics. 2:71–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Linnekamp JF, Butter R, Spijker R, Medema
JP and van Laarhoven HWM: Clinical and biological effects of
demethylating agents on solid tumours-a systematic review. Cancer
Treat Rev. 54:10–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman
RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, et
al: Phase 1b-2a study to reverse platinum resistance through use of
a hypomethylating agent, azacitidine, in patients with
platinum-resistant or platinum-refractory epithelial ovarian
cancer. Cancer. 117:1661–1669. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Matei D, Fang F, Shen C, Schilder J,
Arnold A, Zeng Y, Berry WA, Huang T and Nephew KP: Epigenetic
resensitization to platinum in ovarian cancer. Cancer Res.
72:2197–2205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fang F, Balch C, Schilder J, Breen T,
Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP and Matei
DE: A phase 1 and pharmacodynamic study of decitabine in
combination with carboplatin in patients with recurrent,
platinum-resistant, epithelial ovarian cancer. Cancer.
116:4043–4053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Juergens RA, Wrangle J, Vendetti FP,
Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM,
Franco N, et al: Combination epigenetic therapy has efficacy in
patients with refractory advanced non-small cell lung cancer.
Cancer Discov. 1:598–607. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Singh B, Sarli VN and Lucci A: Inhibition
of resistant triple-negative breast cancer cells with low-dose
6-mercaptopurine and 5-azacitidine. Oncotarget. 12:626–637. 2021.
View Article : Google Scholar : PubMed/NCBI
|
